SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001140361-17-027543
Filing Date
2017-07-10
Accepted
2017-07-10 16:55:15
Documents
2
Period of Report
2017-07-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 1702
2 poawooldridge.htm EX-24 6675
  Complete submission text file 0001140361-17-027543.txt   9833
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AEGLEA BIOTHERAPEUTICS, INC. 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250 AUSTIN TX 78746
Business Address
Wooldridge James (Reporting) CIK: 0001710641 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37722 | Film No.: 17958310